The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Second interim analysis of RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).
 
Marcia S. Brose
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Genzyme; Loxo; Novartis
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Loxo (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Fabian Pitoia
Honoraria - Bayer; Genzyme
Consulting or Advisory Role - Bayer; Genzyme
Speakers' Bureau - Bayer; Genzyme
Travel, Accommodations, Expenses - Bayer; Genzyme
 
Johannes WA Smit
No Relationships to Disclose
 
Chia-Chi Lin
Consulting or Advisory Role - Boehringer Ingelheim; Boehringer Ingelheim; Novartis
Travel, Accommodations, Expenses - Lilly
 
Marc Mardoche Fellous
Employment - Bayer
 
Inga Bayh
Employment - Bayer
Stock and Other Ownership Interests - Fresenius
Consulting or Advisory Role - Fresenius
 
Iwao Sugitani
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bayer; Eisai; Sanofi
Research Funding - Eisai (Inst)
 
Martin Schlumberger
Consulting or Advisory Role - Bayer; Eisai; Genzyme; Ipsen
Research Funding - Bayer (Inst); Eisai (Inst); Exelixis/Ipsen (Inst); Genzyme (Inst)